Skip to main content

Vertex Pharmaceuticals income statement

  • VRTX · Nasdaq
  • Pharmaceuticals
  • Biotechnology
  • S&P 500
$538.60−0.74%Close 13 Nov 2026

Vertex Pharmaceuticals reported revenue of $12.0 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), up 8.9% from fiscal 2024. Net income was $3.95 billion and diluted earnings per share $15.32.

From Vertex Pharmaceuticals's annual and quarterly reports, each period checked against accounting identities; a figure that does not pass is left blank. Fiscal years follow the company's calendar, the latest ending 31 Dec 2025. TTM is the last four reported quarters added up.

Annual

Vertex Pharmaceuticals income statement, annual
USDFY 2008FY 2009FY 2010FY 2011FY 2012FY 2013FY 2014FY 2015FY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025TTM
Revenue$175.5M$101.9M$143.4M$1.41B$1.53B$1.21B$580.4M$1.03B$1.70B$2.49B$3.05B$4.16B$6.21B$7.57B$8.93B$9.87B$11.02B$12.00B$12.95B
Revenue growth—−41.9%+40.7%+884%+8.3%−20.6%−52.1%+77.9%+64.9%+46.2%+22.5%+36.6%+49.1%+22.1%+17.9%+10.5%+11.7%+8.9%—
Net interest income———−$37.68M−$15.04M−$22.93M−$72.86M−$84.21M−$81.43M−$57.55M−$34.12M−$58.50M−$58.20M−$61.50M−$54.80M−$44.10M———
Cost of revenue——$0.00$63.63M$236.7M$88.98M$39.73M$117.2M$210.5M$275.1M$409.5M$547.8M$736.3M$904.2M$1.08B$1.26B$1.53B$1.65B$1.87B
Gross profit——$143.4M$1.35B$1.29B$1.12B$540.7M$915.2M$1.49B$2.21B$2.64B$3.62B$5.47B$6.67B$7.85B$8.61B$9.49B$10.35B$11.08B
Gross margin——100%95.5%84.5%92.7%93.2%88.7%87.6%88.9%86.6%86.8%88.1%88.1%87.9%87.2%86.1%86.2%85.5%
Research and development$516.9M$550.3M$637.4M$707.7M$765.9M$882.1M$855.5M$995.9M$1.05B$1.32B$1.42B$1.75B$1.83B$3.05B—————
Selling, general and administrative$101.3M$130.2M$187.8M$400.7M$432.7M$356.2M$305.4M$376.6M$432.8M$496.1M$557.6M$658.5M$770.5M$840.1M$944.7M$1.14B$1.46B$1.75B$2.41B
Operating expenses——$839.4M————$1.38B$1.48B—$2.00B$2.42B$2.61B$3.89B—————
Operating income−$462.7M−$614.0M−$696.1M$113.8M$46.73M−$610.0M−$692.4M−$466.9M$9.94M$123.2M$635.1M$1.20B$2.86B$2.78B$4.31B$3.83B−$232.9M$4.17B$4.30B
Operating margin−264%—−486%8.1%3.1%−50.3%−119%−45.2%0.6%5.0%20.8%28.8%46.0%36.7%48.2%38.8%−2.1%34.8%33.2%
Interest expense$13.47M$13.19M$19.27M$38.45M$16.65M————$69.30M$72.47M$58.50M$58.15M—$54.80M$44.10M$30.60M$13.30M—
Income before tax−$459.9M−$642.2M−$754.6M$60.45M$32.00M−$626.0M−$734.9M−$557.8M−$67.37M−$15.69M$600.2M$1.39B$3.12B$2.73B$4.23B$4.38B$248.5M$4.64B$4.76B
Income tax expense——$0.00$19.27M−$275.0K−$122.4M$6.96M$30.38M$16.66M−$107.3M−$1.49B$218.1M$405.2M$388.3M$910.4M$760.2M$784.1M$690.0M$783.2M
Effective tax rate——0.0%31.9%−0.9%19.6%−0.9%−5.4%−24.7%684%−248%15.6%13.0%14.2%21.5%17.4%316%14.9%16.5%
Net income−$459.9M−$642.2M−$754.6M$29.57M−$107.0M−$445.0M−$738.6M−$556.3M−$112.1M$263.5M$2.10B$1.18B$2.71B$2.34B$3.32B$3.62B−$535.6M$3.95B$3.98B
Net margin−262%——2.1%−7.0%−36.7%−127%−53.9%−6.6%10.6%68.8%28.3%43.7%30.9%37.2%36.7%−4.9%32.9%30.7%
Net income to common shareholders—−$642.2M−$754.6M$29.29M———−$556.3M−$112.1M———$2.71B——————
EPS · diluted−$3.27−$3.71−$3.77$0.14−$0.50−$1.98−$3.14−$2.31−$0.46$1.04$8.09$4.51$10.29$9.01$12.82$13.89−$2.08$15.32$15.54
Diluted weighted average shares141M173M200M209M215M225M235M241M245M253M259M261M263M260M259M261M258M258M256M
Basic weighted average shares141M173M200M205M212M225M235M241M245M249M254M257M260M258M256M258M258M256M254M
EBITDA−$430.5M−$583.9M−$665.6M$148.9M$84.92M−$561.6M−$629.2M−$404.5M$71.33M$184.6M$707.6M$1.30B$2.97B$2.91B$4.46B$4.01B−$25.70M$4.38B$4.54B
EBITDA margin−245%—−464%10.6%5.6%−46.3%−108%−39.2%4.2%7.4%23.2%31.3%47.8%38.4%49.9%40.7%−0.2%36.5%35.1%
Depreciation & amortization$32.20M$30.11M$30.46M$35.04M$38.19M$48.37M$63.26M$62.34M$61.40M$61.40M$72.42M$106.9M$109.5M$125.6M$148.3M$181.3M$207.2M$209.8M$237.3M
Stock-based compensation$57.98M$86.72M$91.12M$118.2M$114.3M$127.3M$177.5M$231.0M$240.6M$293.2M$325.0M$360.5M$429.5M$441.4M$491.3M$581.2M$698.5M$685.9M$668.6M

Quarterly

Vertex Pharmaceuticals income statement, quarterly
USDQ4 FY2023Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Revenue$2.52B$2.69B$2.65B$2.77B$2.91B$2.77B$2.96B$3.08B$3.19B$2.99B$3.33B$3.44B
Net interest income−$10.60M−$10.40M——————————
Cost of revenue$368.0M$342.6M$371.9M$392.6M$423.4M$363.0M$407.5M$414.8M$466.0M$392.8M$489.2M$526.1M
Gross profit$2.15B$2.35B$2.27B$2.38B$2.49B$2.41B$2.56B$2.66B$2.72B$2.59B$2.84B$2.91B
Gross margin85.4%87.3%85.9%85.8%85.5%86.9%86.3%86.5%85.4%86.8%85.3%84.7%
Selling, general and administrative$369.1M$342.7M$372.2M$371.8M$377.6M$396.4M$424.6M$445.1M$487.0M$493.7M$582.2M$844.1M
Operating income$988.5M$1.14B−$3.51B$1.12B$1.03B$630.1M$1.15B$1.19B$1.21B$1.14B$1.25B$712.9M
Operating margin39.3%42.4%−133%40.3%35.2%22.7%38.8%38.6%37.8%38.1%37.4%20.7%
Interest expense$10.60M$10.40M$9.90M$7.50M$2.80M$3.00M$3.70M$3.30M$3.30M——$36.00M
Income before tax$1.15B$1.28B−$3.39B$1.22B$1.14B$730.4M$1.28B$1.30B$1.33B$1.25B$1.39B$783.4M
Income tax expense$178.8M$179.5M$202.4M$178.7M$223.5M$84.10M$250.1M$215.9M$139.9M$221.5M$292.0M$129.8M
Effective tax rate15.6%14.0%−6.0%14.6%19.7%11.5%19.5%16.6%10.5%17.7%21.0%16.6%
Net income$968.8M$1.10B−$3.59B$1.05B$913.0M$646.3M$1.03B$1.08B$1.19B$1.03B$1.10B$653.6M
Net margin38.5%40.9%−136%37.7%31.4%23.3%34.8%35.2%37.3%34.5%33.0%19.0%
EPS · diluted$3.71$4.21−$13.92$4.01$3.55$2.49$3.99$4.20$4.65$4.02$4.31$2.56
Diluted weighted average shares261M261M258M261M257M260M259M258M256M256M255M255M
Basic weighted average shares258M258M258M258M257M257M257M256M254M254M254M254M
EBITDA$1.05B$1.19B−$3.46B$1.17B$1.07B$678.5M$1.20B$1.24B$1.26B$1.19B$1.30B$782.1M
EBITDA margin41.6%44.3%−131%42.2%36.8%24.5%40.6%40.3%39.5%40.0%39.1%22.7%
Depreciation & amortization$59.00M$53.50M$54.00M$53.20M$46.50M$48.40M$51.70M$54.00M$55.70M$55.90M$56.50M$69.20M
Stock-based compensation$208.6M$191.9M$154.2M$184.6M$167.8M$166.1M$167.3M$194.9M$157.6M$166.4M$170.2M$174.4M

The main figures as JSON and plain text. See data and methodology.

VRTX in the terminal

Every line back twenty years, charts of any figure, segments and KPIs by quarter, valuation and alerts.